12-peptide melanoma vaccine

The **12-peptide melanoma vaccine** is an investigational multipeptide cancer vaccine composed of a mixture of 12 synthetic peptides derived from melanocytic differentiation proteins (including tyrosinase and gp100) and cancer-testis antigens (including MAGE-A1, MAGE-A3, MAGE-A10, and NY-ESO-1). It was designed primarily for patients with melanoma and formulated to stimulate CD8+ cytotoxic T lymphocyte responses by presenting these peptide antigens, which are restricted by the most common human leukocyte antigen (HLA) types (A1, A2, and A3), to a broad population of melanoma patients. Its primary indication has been for high-risk and advanced-stage melanoma, and it has been investigated as monotherapy and in combination with helper peptides and immune adjuvants, such as GM-CSF and Montanide ISA-51. The vaccine aims to induce a robust, multi-antigen T cell immune response to counteract tumor heterogeneity and immune evasion. Multiple clinical trials have shown that it is immunogenic and well tolerated, inducing detectable CD8+ T cell responses in most treated patients[1][3][4][5]. Long-term follow-up suggests some survival benefit in certain patient subsets, but definitive improvement in clinical outcomes remains investigational[2][5].

Other names

multipeptide melanoma vaccine12MP melanoma vaccine